Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Background Inspired by nature, the biomimetic approach has been incorporated into drug
nanocarriers for cancer targeted chemotherapy. The nanocarriers are cloaked in cell …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …